GlassScriptPhysician profile
Natalie U Nicholson
NPI 1780105924
$4,193.78
in general payments reported to CMS, 2019-2025
28 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $309 · 2024: $1,765 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,116 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,115.81 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,031.49 | 2023-2025 | Erleada, Carvykti, Rybrevant |
| Abbvie INC. | $503.87 | 2024-2025 | |
| Olympus America INC. | $493.12 | 2024-2025 | Itind System |
| Sumitomo Pharma America, INC. | $322.74 | 2024-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $277.55 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $254.87 | 2024-2025 | Lithovue, Lithoclast, Rezum Generator |
| Astellas Pharma US INC | $213.77 | 2023-2025 | Xtandi |
| Teleflex LLC | $156.95 | 2024-2025 | Urolift, Barrigel |
| Ferring Pharmaceuticals INC. | $154.59 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $114.07 | 2025 | |
| Dendreon Pharmaceuticals LLC | $87.35 | 2023-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $82.43 | 2023-2025 | |
| Biotissue Holdings INC. | $79.98 | 2025 | |
| Innovation Technologies INC | $68.27 | 2024 | Irrisept |
| Endo USA, INC. | $60.35 | 2024-2025 | Xiaflex, Aveed |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $50.35 | 2023-2025 | Jelmyto |
| Tolmar, INC. | $33.03 | 2024 | |
| Merck Sharp & Dohme LLC | $26.28 | 2024 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $25.25 | 2024 | Lynparza |
| Kerecis Limited | $22.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbott Laboratories | $21.65 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $18.00 | 2025 | |
| Cycle Pharmaceuticals INC | $17.68 | 2024 | Tiopronin |
| Blue Earth Diagnostics | $16.50 | 2023 | |
| Immunitybio, INC. | $16.29 | 2024 | |
| Progenics Pharmaceuticals, INC. | $15.85 | 2025 | |
| Millicent US INC | $15.56 | 2024 | Intrarosa |
| Endo Pharmaceuticals INC. | $13.19 | 2023 | Aveed, Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.